Prestige BioPharma KRX:950210KOSPI
프레스티지바이오파마 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days2
Articles tracked0since Sep 11
In Q4 2025, Prestige BioPharma reported revenue of ₩5m, up 140.6% year on year, and an operating loss of ₩13m. Prestige BioPharma (프레스티지바이오파마) appeared in 0 Korean news articles and 2 DART filings over the past seven days.
Filing signals 4 quarters of losses Screener
Prestige BioPharma quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q4 2025 | ₩5m | +140.6% | −₩13m | −₩14m |
| Q3 2025 | ₩2m | +1.9% | −₩18m | −₩15m |
| Q2 2025 derived | – | – | −₩10m | −₩6m |
| Q1 2025 | – | – | −₩11m | ₩33m |
| Q4 2024 | ₩2m | – | −₩15m | −₩16m |
| Q3 2024 | ₩2m | – | −₩11m | −₩8m |
| Q2 2024 derived | – | – | −₩7m | −₩9m |
| Q1 2024 | – | – | −₩13m | −₩10m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Prestige BioPharma top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Prestige BioPharma news Korean headlines
No articles yet.